As Q1 2026 earnings season begins, the article identifies 10 undervalued US stocks expected to report earnings within 10 days. These stocks appear undervalued by 36-60% based on fair value estimates, with analysts projecting potential gains of 22-117%. Three highlighted stocks are Churchill Downs (gaming/entertainment), Gentex (automotive vision systems), and Omnicell (hospital automation), all showing strong analyst support despite recent stock declines.

The global robotic pharmacy prescription market is experiencing significant growth, expanding from USD 214.16 million in 2025 to USD 237.65 million in 2026, with a projected CAGR of 9.18% through 2032, reaching USD 396.21 million. The market is driven by automation adoption for medication safety and efficiency, workforce transformation toward clinical roles, and bundled solution procurement strategies across hospitals, clinics, and long-term care facilities.

Omnicell's EVP & Chief Legal/Admin Officer Corey Manley sold 6,106 shares worth $243,629 on December 3, 2025, reducing his direct holdings by 5.85%. The sale occurred as the stock approached 52-week highs following strong Q3 results and the announcement of the company's new Titan XT automated dispensing system, which prompted analyst upgrades.

Evoke Pharma partnered with EVERSANA and Omnicell to expand access to GIMOTI nasal spray for gastroparesis treatment, targeting large gastroenterology practices and specialty pharmacies through strategic pharmacy network agreements.

The global pharmacy automation market is projected to grow from USD 6.99 billion in 2025 to USD 16.65 billion by 2034, driven by technological advancements, chronic disease management, and the need to reduce medication errors.

Several mid-cap stocks, including Globalstar, V.F. Corp, and Madrigal Pharmaceuticals, were among the top gainers last week. The companies reported positive financial results and business updates, leading to the stock price increases.

The global adherence packaging market size is expected to grow from $1.10 billion in 2023 to $1.93 billion by 2032, driven by the increasing number of chronic diseases and the need for quality medication. However, high costs and strict regulations pose challenges to the market's growth.

A robust Advanced Services portfolio and strategic restructuring initiatives bode well for Omnicell (OMCL).

Inspire (INSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

With the EnlivenHealth platform, Omnicell (OMCL) is gaining momentum with cross-selling and up-selling communication solutions to existing customers.

Omnicell (OMCL) outpaces expectations in the first quarter of 2024 in a challenging customer environment.

Omnicell (OMCL) delivered earnings and revenue surprises of 137.50% and 4.43%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?